


**Amendments to the Claims:**

This listing of claims will replace all prior versions and listings of claims in the application.

**Listing of Claims:**

1-10. (Canceled)

11. (Currently Amended<sup>1</sup>) ~~The A compound of claim 5 according to the structure~~



~~wherein at least one of R<sub>2</sub>, R<sub>3</sub> or R<sub>4</sub> is OH and and at least one of R<sub>2</sub>, R<sub>3</sub>~~

~~wherein R<sub>4</sub> or R<sub>5</sub> is NO<sub>2</sub> and the other of R<sub>4</sub> or R<sub>5</sub> is H,~~

~~or a pharmaceutically acceptable salt thereof.~~

~~; or wherein at least one of R<sub>2</sub>, R<sub>3</sub> and R<sub>4</sub> is OH, at least one of R<sub>2</sub>, R<sub>3</sub>, R<sub>4</sub>, R<sub>5</sub> or R<sub>6</sub> is the alkyl, and R<sub>4</sub> is SO<sub>2</sub>CH<sub>3</sub>, SO<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>, SO<sub>2</sub>(CH<sub>2</sub>)<sub>2</sub>CH<sub>3</sub> or SO<sub>2</sub>(CH<sub>2</sub>)<sub>3</sub>CH<sub>3</sub>.~~

12-18. (Canceled)

19. (Currently Amended) A method of inducing apoptosis in human breast cancer cells comprising contacting the cancer cell with the compound of claim 11 ~~any one of claims 5-17.~~


<sup>1</sup> In the Reply dated June 19, 2007, claim 11 was incorrectly noted as being "Original." The status should have been "Currently Amended."

20. (Currently Amended) A method of treating human breast cancer in a subject in need of said treatment, comprising administering to the subject the compound of claim 11 ~~any one of claims 5-17~~.

21. (Original<sup>2</sup>) The method of claim 20 wherein said method further comprises administering calcium glucarate to the subject.

22. (New) The compound of claim 11, wherein the salt is a hydrochloride salt or a pyridine salt.

23. (New) A pharmaceutical composition comprising:  
a compound according to the structure



wherein R<sub>4</sub> or R<sub>5</sub> is NO<sub>2</sub> and the other of R<sub>4</sub> or R<sub>5</sub> is H,  
or a pharmaceutically acceptable salt thereof, and,  
a pharmaceutically acceptable carrier.

---

<sup>2</sup> Claim 21 should not be withdrawn because it depends from claim 20, which is not withdrawn, and because claim 21 merely adds an additional step.